We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Five Serologic Tests Evaluated for Threadworm Infection Follow-Up

By LabMedica International staff writers
Posted on 25 Feb 2015
Traditional fecal-based methods have poor sensitivity for the detection of Strongyloides stercoralis, therefore are inadequate for post-treatment evaluation of infected patients who should be carefully monitored to exclude the persistence of the infection.

The performance of the five serological tests has been compared for the follow up of patients after treatment, who were infected with S. More...
stercoralis or threadworm, in order to identify if antibody decline could be used a surrogate marker for cure, in addition to negative stools.

Scientists at the Center for Tropical Diseases, Sacro Cuore Hospital (CTD; Verona, Italy) and an international team carried out retrospective study on archived, anonymized sera available at the CTD. Samples were classified according to a composite reference standard, a procedure used for evaluation of diagnostic tests when there is no gold standard: a) positive: positive fecal tests and/or at least 3/5 positive serologic tests; b) negative: negative fecal tests and less than three positive results out of the five serologic tests.

The samples were tested with two commercially-available enzyme-linked immunosorbent assays (ELISA) for Strongyloides (IVD Research; Carlsbad, CA, USA, and Bordier Affinity Products; Crissier, Switzerland), and three noncommercial tests: immunofluorescence antibody test (IFAT), recombinant Strongyloides antigen (NIE) enzyme-linked immunosorbent assay (NIE-ELISA), and the NIE- luciferase immunoprecipitation systems (NIE-LIPS).

A high proportion of samples demonstrated for each test a seroreversion or a relevant decline in optical density/relative light units halved or decreases of at least two titers for IFAT at follow up. The results confirmed by the linear mixed effects model that showed a trend to seroreversion over time for all tests. In particular, IVD-ELISA where almost 90% samples demonstrated relevant decline and almost 87% of IFAT had the best performances. Considering only samples with a complete negativization, NIE-ELISA showed the best performance with 72.5% seroreversion.

The authors that concluded that each of the serology tests considered can be used for monitoring patients who received a treatment for S. stercoralis infection. Serology, in combination with fecal-based methods, should be used as the preferred tool for the follow up. Validation of polymerase chain reaction (PCR) techniques for the follow up might be a useful support for situations of uncertainty such as patients with serology values that do not seem to decrease over time. The study was published on February 10, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Center for Tropical Diseases
IVD Research
Bordier Affinity Products 



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Host Response Immunoassay Test
MeMed BV
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.